Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01392300 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
A Phase 3 study of Post-stroke Spasticity of the Upper Limb, sponsored by Merz Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 317
- Enrollment target
- 20
- Study locations
NCT01392300: Completed Phase 3 study of Post-stroke Spasticity of the Upper Limb, sponsored by Merz Pharmaceuticals.
NCT01392300 is a Phase 3 study of Post-stroke Spasticity of the Upper Limb that has completed, run by Merz Pharmaceuticals. The registered enrollment target is 317 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01392300, a Phase 3 study of Post-stroke Spasticity of the Upper Limb, has completed, sponsored by Merz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 317 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.
Primary Outcome
Primary target clinical pattern was defined by investigator for each subject at baseline visit and was either flexed wrist or clenched fist or flexed elbow. The Ashworth Scale is well known and commonly used in clinical trials with spasticity. It was used to categorize severity of spasticity by judging resistance to passive movement. It is a 5-point scale that ranges from 0 (=no increase in tone) to 4 (=limb rigid in flexion or extension).
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG IncobotulinumtoxinA (400 Units)
Study Locations (20)
Other
- Merz Investigational Site #420046 - Brno
- Merz Investigational Site #420029 - Brno
- Merz Investigational Site #420028 - Olomouc
- Merz Investigational Site #420024 - Ostrava-Poruba
- Merz Investigational Site #420025 - Pardubice
- Merz Investigational Site #420030 - Prague
- Merz Investigational Site #420045 - Prague
California
- Merz Investigational Site #001184 - Downey
- Merz Investigational Site #001017 - Fountain Valley
North Carolina
- Merz Investigational Site #001240 - Chapel Hill
- Merz Investigational Site #001009 - Winston-Salem
Pennsylvania
- Merz Investigational Site #001241 - Philadelphia
- Merz Investigational Site #001211 - Pittsburgh
Florida
- Merz Investigational Site #001188 - Miami
Georgia
- Merz Investigational Site #001037 - Augusta
Illinois
- Merz Investigational Site #001186 - Chicago
Kansas
- Merz Investigational Site # 001110 - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
What the finished NCT01392300 record still lists
NCT01392300 is an interventional study that assigns participants to a tested intervention. The registered 317 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Post-stroke Spasticity of the Upper Limb appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT01392300 names 20 study sites across 11 states, led by Other, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01392300 about?
NCT01392300 is a clinical study titled "Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke". The purpose of this study is to determine whether injections of Botulinum toxin type A into muscles of the upper limb are effective in treating spasticity in patients after stroke.
What is the current status of trial NCT01392300?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 317 participants. The study started on 2011-09. Estimated completion is 2014-02.
What conditions does trial NCT01392300 study?
This clinical trial studies the following conditions: Post-stroke Spasticity of the Upper Limb.
What interventions are being tested in trial NCT01392300?
The interventions under investigation include: Placebo Comparator (DRUG), IncobotulinumtoxinA (400 Units) (DRUG).
Who is sponsoring clinical trial NCT01392300?
This trial is sponsored by Merz Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01392300 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01392300's enrollment target sits among peer trials
317 1089th of 2000 higher than 911 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04594642 · 317 participants · Phase 1
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
- NCT04977453 · 317 participants · Phase 1
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- NCT05137054 · 317 participants · Phase 1
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- NCT05382754 · 317 participants · NA
Home Apnea Testing in CHildren Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia